Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:51:00 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:EOLS - EVOLUS INC - https://investors.evolus.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EOLS - Q0.712.37·12.400.312.37-0.63-4.8311.23,6164,41513.00  13.10  12.31517.82  9.2515:32:5908:0015 min RT 2¢

Recent Trades - Last 10 of 4415
Time ETExPriceChangeVolume
15:33:09Q12.3751-0.62499
15:33:05Q12.3781-0.621976
15:33:05Q12.3999-0.600117
15:32:59Q12.3719-0.62811
15:32:43Q12.3741-0.62597
15:32:38Q12.3742-0.625817
15:32:27Q12.37-0.63200
15:32:21Q12.3767-0.623356
15:32:18Q12.3756-0.624415
15:31:57Q12.3957-0.60436

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-25 08:00U:EOLSNews ReleaseEvolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
2025-03-21 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-04 16:05U:EOLSNews ReleaseEvolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
2025-02-27 08:00U:EOLSNews ReleaseEvolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
2025-02-20 08:00U:EOLSNews ReleaseEvolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
2025-02-18 08:00U:EOLSNews ReleaseEvolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
2025-02-13 13:30U:EOLSNews ReleaseEvolus Announces FDA Approval of Evolysse(TM) Form and Evolysse(TM) Smooth Injectable Hyaluronic Acid Gels
2025-02-07 19:09U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-21 08:00U:EOLSNews ReleaseEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance
2025-01-17 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-13 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-06 16:05U:EOLSNews ReleaseEvolus Reports Third Quarter 2024 Results
2024-11-01 08:00U:EOLSNews ReleaseEvolus to Participate in Stifel 2024 Healthcare Conference
2024-10-31 14:02U:EOLSNews ReleaseEvolus Announces EU Approval of Estyme(TM) Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
2024-10-29 08:00U:EOLSNews ReleaseEvolus Rewards(TM) Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
2024-10-23 08:00U:EOLSNews ReleaseEvolus to Report Third Quarter Financial Results on November 6, 2024
2024-10-11 22:53U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-27 21:00U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-06 08:00U:EOLSNews ReleaseEvolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
2024-08-09 16:30U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)